Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
146.10
-0.28 (-0.19%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Neurocrine Biosciences Employees
Neurocrine Biosciences had 2,500 employees as of June 30, 2026. The number of employees increased by 700 or 38.89% compared to the same quarter last year. That makes Neurocrine Biosciences the 8,991st largest employer in the world and 1,562nd in the United States.
Employees
2,500
Change (1Y)
700
Growth (1Y)
38.89%
Revenue / Employee
$1,349,560
Profits / Employee
$282,200
Market Cap
14.85B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 2,500 | 700 | 38.89% |
| Dec 31, 2025 | 2,000 | 200 | 11.11% |
| Dec 31, 2024 | 1,800 | 400 | 28.57% |
| Dec 31, 2023 | 1,400 | 200 | 16.67% |
| Dec 31, 2022 | 1,200 | 300 | 33.33% |
| Dec 31, 2021 | 900 | 55 | 6.51% |
| Dec 31, 2020 | 845 | 145 | 20.71% |
| Dec 31, 2019 | 700 | 115 | 19.66% |
| Dec 31, 2018 | 585 | 185 | 46.25% |
| Dec 31, 2017 | 400 | 204 | 104.08% |
| Dec 31, 2016 | 196 | 76 | 63.33% |
| Dec 31, 2015 | 120 | 26 | 27.66% |
| Dec 31, 2014 | 94 | 13 | 16.05% |
| Dec 31, 2013 | 81 | 3 | 3.85% |
| Dec 31, 2012 | 78 | 7 | 9.86% |
| Dec 31, 2011 | 71 | 5 | 7.58% |
| Dec 31, 2010 | 66 | 1 | 1.54% |
| Dec 31, 2009 | 65 | -60 | -48.00% |
| Dec 31, 2008 | 125 | -10 | -7.41% |
| Dec 31, 2007 | 135 | -132 | -49.44% |
| Dec 31, 2006 | 267 | -321 | -54.59% |
| Dec 31, 2005 | 588 | 203 | 52.73% |
| Dec 31, 2004 | 385 | 40 | 11.59% |
| Dec 31, 2003 | 345 | 69 | 25.00% |
| Dec 31, 2002 | 276 | 54 | 24.32% |
| Dec 31, 2001 | 222 | 34 | 18.09% |
| Dec 31, 2000 | 188 | 37 | 24.50% |
| Dec 31, 1999 | 151 | 2 | 1.34% |
| Dec 31, 1998 | 149 | 41 | 37.96% |
| Dec 31, 1997 | 108 | 5 | 4.85% |
| Dec 31, 1996 | 103 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,527 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
NBIX News
- 9 hours ago - Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia - PRNewsWire
- 4 days ago - Neurocrine presents new analysis establishing benchmark in dyskinesia treatment - TheFly
- 4 days ago - Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia - PRNewsWire
- 8 days ago - Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome - PRNewsWire
- 10 days ago - Neurocrine begins Phase 2 study of NBI-‘567 in adults with Alzheimer’s disease - TheFly
- 10 days ago - Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease - PRNewsWire
- 14 days ago - Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia - PRNewsWire
- 18 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - PRNewsWire